At QuCiL Health, we understand the profound impact that depression can have on an individual’s life. For those who have not found relief through traditional treatments, we offer SPRAVATO® (esketamine) as a revolutionary option for the treatment of treatment-resistant depression (TRD) and depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.
Treatment-Resistant Depression is defined as a major depressive disorder (MDD) that has not responded to at least two different antidepressant treatments given at adequate doses and duration. It affects millions of adults worldwide and can significantly impair one’s quality of life.
SPRAVATO® is an FDA-approved nasal spray used in conjunction with an oral antidepressant and/or psychotherapy, for adults with TRD and MDD with increased suicidality. It targets the NMDA receptors in the brain, offering a new mechanism of action compared to traditional antidepressants.
For individuals whose depressive symptoms have not improved after the use of other antidepressants with or without psychotherapy.
SPRAVATO® is also approved for depressive symptoms in adults with MDD who have acute suicidal thoughts or behaviors.
SPRAVATO® is self-administered under medical supervision in our clinic to ensure safety and efficacy.
Patients are monitored by healthcare professionals during and after treatment due to the potential for sedation and dissociation.
The frequency and duration of treatment are tailored to each patient’s needs, with adjustments made based on response to the medication.
At QuCiL Health, we provide innovative and compassionate care for those struggling with TRD and MDD with increased suicidal thoughts or behavior. Our team of experienced professionals will support you through every step of the treatment process, ensuring a safe and comfortable experience.
At QuCiL Health, we offer SPRAVATO® (esketamine) nasal spray as a part of our mental health services for individuals adults with Treatment-Resistant Depression (TRD) and MDD with increased suicidality. While SPRAVATO® can be a life-changing treatment option, it’s essential to understand both its benefits and potential side effects. While SPRAVATO® has been shown to be effective for many patients, like all medications, it can cause side effects. The most common side effects include:
Sedation: Feeling excessively sleepy or drowsy after treatment.
Dissociation: Feeling disconnected from yourself, your thoughts, feelings, and surroundings.
Dizziness: Experiencing a sensation of spinning or lightheadedness.
Nausea: Feeling the urge to vomit.
Vertigo: A sense that you or your surroundings are moving or spinning.
Increased Blood Pressure: Significant elevation in blood pressure shortly after taking the medication.
Cognitive Impairment: Difficulty with thinking or decision-making.
Since SPRAVATO® carries a risk for sedation and dissociation, it is administered under the supervision of a healthcare provider at a certified medical office or clinic. Patients are monitored for at least two hours after administration due to the potential for these side effects.
SPRAVATO® is only available through a restricted program called the Risk Evaluation and Mitigation Strategy (REMS) due to the potential for abuse and serious side effects. This program ensures that SPRAVATO® is administered in a safe and controlled environment.
At QuCiL Health, your safety is our top priority. We provide a supportive and monitored environment for SPRAVATO® treatment, ensuring that you receive comprehensive care tailored to your needs. Our team of experts will discuss all aspects of treatment with you, including potential side effects, to ensure you make an informed decision about your care.
These stories reflect the potential life-changing effects of SPRAVATO® for individuals with TRD and MDD with increased suicidality. It’s important to note that while these patients have had positive experiences, responses to treatment can vary, and it’s essential to consult with a healthcare provider to determine the best course of action for your individual needs.
Success stories and patient testimonials related to SPRAVATO® treatment for Treatment-Resistant Depression (TRD) and MDD with increased suicidality:
Inform your healthcare provider about any side effects you’re experiencing. They can provide guidance on how to manage them and determine if any changes to your treatment are necessary.
Keep track of the side effects and their severity. This information will be helpful for your healthcare provider to assess your situation.
It’s crucial not to stop your SPRAVATO® treatment without consulting your healthcare provider, even if you’re experiencing side effects.
If the side effects seem life-threatening or if you think you’re having a medical emergency, call 911 or your local emergency number right away.
Remember, your safety is paramount, and your healthcare provider is there to support you throughout your treatment. It’s always best to communicate openly with them about your experiences and concerns.
QuCiL Health™
Proud Member of
QuCiL Health ™ is a Trademark of Synergy PrimeCare PLLC. All rights reserved.
